个体化卵巢刺激联合方案的多中心探索性研究
这项多中心、开放标签、探索性研究纳入110名18-40岁患者,采用个体化剂量follitropin delta联合HP-hMG的混合方案进行控制性卵巢刺激。结果显示,与ESTHER-1试验中单用follitropin delta相比,本方案获卵数和优质囊胚数显著更高,但任何级别OHSS发生率也更高(9.3% vs 2.6%),无中重度OHSS。
要点
- 个体化follitropin delta联合HP-hMG可显著提高获卵数和优质囊胚数
- 任何级别OHSS发生率为9.3%,无中重度OHSS,无需医疗干预或住院
- 本队列GnRH激动剂触发率43%,显著高于ESTHER-1的2.3%
核心结论
- 个体化剂量follitropin delta联合HP-hMG的混合方案可显著增加第5天和第6天可用囊胚数,但轻度OHSS风险增加,无需医疗干预或住院。
研究设计与样本
- 多中心、开放标签、探索性研究,纳入110名18-40岁患者,与ESTHER-1试验中follitropin delta组进行队列比较。
主要发现
- 按年龄分层后,本研究的平均获卵数和优质囊胚数均显著高于ESTHER-1中单用follitropin delta的组。
- 本队列GnRH激动剂触发率为43%,显著高于ESTHER-1 follitropin delta组的2.3%。
- 任何级别OHSS发生率为9.3%,高于ESTHER-1 follitropin delta组的2.6%;本研究中无中重度OHSS,而ESTHER-1组为1.4%。
关键数值与推荐
- follitropin delta剂量按既定算法固定,HP-hMG剂量为:follitropin delta起始剂量<12 μg时75 IU;12 μg且体重<100 kg时150 IU;12 μg且体重≥100 kg时225 IU。
- 剂量调整仅限于HP-hMG。
临床怎么用
- 对于接受IVF控制性卵巢刺激的患者,可考虑个体化follitropin delta联合HP-hMG的混合方案以提高可用囊胚数,但需警惕轻度OHSS风险增加。
局限性
- 本研究为开放标签、探索性研究,样本量110例,与ESTHER-1试验进行非随机队列比较,可能存在混杂偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety profile and the number of usable blastocysts on day 5 and on day 6 after treatment with an individualized dosing regimen of a follitropin delta and highly purified human menopausal gonadotropin (HP-hMG) for controlled ovarian stimulation. DESIGN: Multicenter, open label, exploratory study. SETTING: Reproductive medicine clinics. PATIENT(S): A total of 110 patients (aged 18-40 years). INTERVENTION(S): Follitropin delta coadministered with HP-hMG, with follitropin delta dose fixed according to an established algorithm and HP-hMG dose at 75 IU when the follitropin delta starting dosage was <12 μg; 150 IU when follitropin delta dosage was 12 μg and weight <100 kg, and 225 IU when follitropin delta dosage was 12 μg and weight ≥100 kg (dosage adjustments confined to HP-hMG only). MAIN OUTCOME MEASURE(S): Mean number of good-quality blastocysts obtained at day 5 and day 6 as well as the proportion of women with ovarian hyperstimulation syndrome (OHSS). RESULT(S): A cohort study was compared with the follitropin delta group from the Evidence-based Stimulation Trial with Human Recombinant Follicle-Stimulating Hormone in Europe and Rest of World 1 (ESTHER-1) study. Even when stratified by age, a statistically significantly higher mean in the number of oocytes retrieved and number of good-quality blastocysts was observed in this study compared with the ESTHER-1 trial in which follitropin delta was used alone. The rate of patients triggered with a gonadotropin-releasing hormone agonist was statistically significantly higher in our Menopur and Rekovelle Combined Study (MARCS) cohort (43%) when compared with the rates reported in the follitropin delta cohort in the ESTHER-1 study (2.3%). Incidence of any grade of OHSS was 9.3% in the present study compared to 2.6% in follitropin delta group from ESTHER-1 trial. No cases of moderate or severe OHSS were observed in our study compared with 1.4% in the follitropin delta group of ESTHER-1. CONCLUSION(S): Optimizing the ovarian response during in vitro fertilization employing a mixed protocol of individualized dosing of follitropin delta and HP-hMG resulted in a statistically significant number of usable blastocysts on days 5 and 6 with an increased risk of mild OHSS, which did not require medical intervention or hospitalization. CLINICAL TRIAL REGISTRATION NUMBER: NCT03483545.
引用
- Bissonnette F, Minano Masip J, Kadoch IJ, et al. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil Steril. 2020. PMID: 33267959. doi:10.1016/j.fertnstert.2020.09.158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。